New technologies delivered to your inbox Subscribe
2000-025 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More
2000-013 – The development of a delivery mechanism (pill or capsule) for barium sulfate which is used for the purpose of altering the density of stool sufficiently that it can be electronically subtracted. A new software tool (computer algorithm) for electronic subtraction of contrast-laden stool has been developed.
1999-095 – This invention will help allow very high field strength MRI systems to be used safely and effectively as clinical systems for routine patient use.
1999-065 – Investigators are combining mEPO and together with mEPO deficient gene knock-out animals to create a battery of monoclonal antibodies against this eosinophil granular ribonuclease. Highly specific, sensitive antibodies will be produced that will be useful in assays and drug discovery programs for eosinophil-related diseases such as asthma, allergy and inflammation.
1999-064 – Investigators have developed a rabbit polyclonal antisera reactive against murine major basic protein-1 (native protein purified from isolated mouse eosinophils). MBP is a known factor in the asthma, inflammation and allergy pathways. This antibody is highly specific and would be useful in a variety of assays where high specificity and sensitivity are desired.
1999-061 – This is a cell therapy delivery system which allows efficient and long term vascular delivery.
Self-Terminating High-Speed Low-Power Logic Transceiver Enabling Compatibility Between CMOS Based Logic Devices of Differing Supply Voltages
1999-056 – A CMOS based digital output buffer circuit and input buffer circuit, with both circuits forming a transceiver pair, is described. The transceiver enables high speed point-to-point digital communication and hence cannot be used for multi-drop digital buses. The transceiver offers many of the features desired of transceivers. These features include: a) Compliance between transmitting devices... Read More
1999-038 – Naturally produced tumor suppressors can be used to prevent and treat bone tumors.
1999-036 – AVWPC is a comprehensive set of imaging functions which facilitates full exploration and analysis of multidimensional, multimodality biomedical image data sets that runs on PCs using C compilers and operating systems such as Windows. The software also facilitates the development and implementation of advanced imaging algorithms and techniques and easy integration of these into specific... Read More
1999-033 – These methods reduce the audible sound produced by ultrasound scanners in patients. Reduction of fetal stress during ultrasound examination.
1999-020 – A successful computational method was developed to perform molecular dynamics simulations of zinc’s tetrahedral coordination and the exchanges of zinc ligands in proteins for studies of thermodynamic properties of zinc proteins in water including evaluation of binding free energies of zinc ligands. This method enables expeditious search of effective antiangiogenesis and antiproliferation... Read More
1999-003 – Polyclonal antibody and purification thereof that recognizes the Amyloid B. peptide (AB).
1998-097 – A method is described that allows both highly sensitive screening for arterial disease in conjuction with highly specific diagnoses on an MR System with high-speed gradients.
1998-076 – Short term paralysis of underlying musculature to improve cutaneous wound healing in tramatic and non-tramatic wounds.
1998-071 – Substrates for SULT1A1 are; 4-nitrophenol, 17beta-estradiol (E2), diethylstilboestrol (DES), 1-naphol, 4-hydroxytamoxifen, minoxidil, estrone (E1), epinephrine, dopamine, acetaminophen, genistein, other monocyclic phenols. The gene is ubiquitously expressed but especially prominent in liver but also lung, brain, platelet, prostate, placenta, and adrenal gland. Diseases associated with... Read More
1998-066 – The Mayo Clinic is developing and testing a synbiotic (composition of synergistic probiotic organisms and a prebiotic) for clinical indications (Croh'n’s, IBD, immunocompromised patients, patients undrgoing chemo or radiation therapy, patients infected with antibiotic resistant organisms. THe synbiotic has proven to be very effective in several animal trials including animals that were... Read More
1998-060 – A stent that fractures at strategic points to relieve arterial stress after placement.
1998-036 – Histamine N-methyltransferase (HNMT, EC126.96.36.199) catalyzes a major pathway in the metabolism of histamine. The only pathway for the termination of the neurotransmitter actions of histamine in the human CNS is N-methylation catalyzed by HNMT, and approximately 70% of histamine in bronchial epithelium is metabolized by HNMT. Mayo investigators have cloned the cDNA and gene for HNMT in humans and... Read More
1998-026 – Mutations in the tau gene have been discovered that are linked to Tau pathologies. Identification of these mutations can lead to animal models of neurodegenerative diseases to be developed and provides methods for determining a diagnosis of neurodegenerative disease in a patient.
1998-009 – Multiple myeloma is a universally fatal plasmaproliferative disorder despite aggressive chemotherapy and transplantation. An immunotherapeutic approach to target myeloma cells for killing by toxin genes or radioisotopes may be very useful therapeutically in myeloma and such approaches have already been shown to have clinical activity in other malignancies. Our investigators have devised a... Read More
1997-112 – An inbred strain of transgenic mice that show tissue-specific expression of the human MUC1 gene. These animals express a form of the human MUC1 gene which codes for the core protein of a mucin expressed by glandular epithelia and carcinomas which develop from these tissues. The core protein is underglycosylated in these cancers and therefore represents a possible target for immunotherapy.... Read More
1997-109 – System for clinical image display.
1997-106 – Mayo researchers have established several human multiple myeloma cell lines, including the ANBL-6, KP-6, KAS-6/1 and DP-6 lines.
1997-103 – Expanding screw with increased strength of bone-screw interface for spinal internal fixation surgeries.
1997-072 – We generated mice transgenic for HLA-DQ6, an allele associated with a nonsusceptible haplotype. These mice were found to be resistant to collagen induced arthritis. These mice are a model for rheumatoid arthritis.
1997-071 – We generated an HLA-DR4ß(NT) transgene construct in which positions 110 and 139 were altered to resemble endogenous mouse H2 Aß molecules. This construct was introduced into (B10 x SWR) embryos, and DR4ß(NT) transgenic mice were produced. The transgene was transferred into B10.RFB3 (Eß0 Ealphap) mice. The transgene-encoded DR4ß molecules paired with endogenous Ealpha chains to form stable... Read More
1997-069 – We developed an HLA-DR2 mouse model by introducing a human DRB1*1502(DR2DW12) transgene into CIA susceptible BIO.RQB3 (H2A8) mice. These mice showed a significant reduction in the incidence and severity of arthritis. For further information please see Human Immunology, 1996, 50:54-60.
1997-035 – This technology is a T-cell line that lacks the protein tyrosine kinase, ZAP-70. ZAP-70 plays a critical role in the initiation of lymphocyte activation responses to antigenic stimuli. The cell line can be used to define the mechanisms of ZAP-70 activation and function in T-cell signaling. This line can be used also to confirm the mechanism of action of ZAP-70 targeted drugs. This is the... Read More
1997-014 – A novel, topical chemotherapeutic drug in vanishing cream to treat malignancy.
1997-001 – With the aging of the population, osteoporosis is emerging as a major public health problem. Drugs used to treat osteoporosis can be classified into those that decrease bone resorption and those that increase bone formation. While a number of anti-resorptive therapies for osteoporosis are presently available, there is a clear need for novel anabolic approaches. New insights gained from a... Read More
1996-112 – Enable clinicians to selectively cool the brain, independent of core temperature, as a means of cerebral protective therapies.
1996-106 – Mayo has issued patent claims for inhibiting hydroxymethylglutaryl coA reductase activity to slow heart valve degeneration.
1996-100 – Radiation force of arbitrary frequency is generated on the object using a single ultrasound beam. This system is used for information transmission, object detection or imaging. 3D blood flow vector imaging and imaging of internal structures of living cells.
1996-076 – Transgenic mouse (Tg2576) carrying the Swedish mutation for Alzheimer’s Disease. This mouse was developed by Dr. Karen Hsiao Ashe at the University of Minnesota and is exclusively licensed to Mayo. This mouse develops age-related neuropathology, including development of amyloid plaques and behavioral changes, and can be used in research related to Alzheimer’s Disease and other... Read More
1995-155 – HFOBER cells are hFOBs stably transfected with human estrogen receptor; subclones HFOB/ER-3 and HFOB/ER-4 express levels of estrogen receptor consistent with the range of levels measured in human osteoblasts. The HFOBER cell lines have a complete concatenation of transcription factors such that the estrogen receptor is transactionally active; estrogen-regulated functions are maintained. The... Read More
1995-140 – Transgenic mouse models for asthma were developed that express interleukin-5 under the control of a lung epithelial specific promoter. All mice express abnormally high levels of eosinophils in those regions and display symptoms consistent with the underlying physiologic conditions. The CCIL-5 mouse line is a superb animal model for the study of asthma. The animals show hyperactivity to... Read More
1995-139 – Transgenic mouse models for eosinophil-mediated tissue inflammation were developed that express interleukin-5 under the control of a T-cell specific promoter. All mice express abnormally high levels of eosinophils in those regions and display symptoms consistent with the underlying physiologic conditions. The NJ1638 mice are models for hypereosinophilic syndromes and have high levels of... Read More
1995-134 – A statistical learning algorithm about average left ventricular (LV) geometry is described. It allows a knowledgeable recovery of the LV boundry from sparse ultrasound data and minimal user-supplied clues. Objective analysis of LV function in artifact-prone ultrasound images of the heart.
1995-110 – These radiolabeled agents are designed to allow for simple preparation of radioactive markers for measuring colonic transit without the need for an Investigational New Drug application (IND). These radiolabeled agents can be used to evaluate patients with suspected colonic motility disorders.
1995-102 – Detection with the use of broad range primers and the PCR assay for the detection of the WA-1 Agent.
1995-101 – Mayo Clinic researchers have developed a PCR test for granulocytic ehrlichia.
1995-094 – In this system, a low frequency radiation force is exerted point-by-point on the object by a confocal ultrasound transducer. The amplitude of the resulting acoustic field is used to produce a two-dimensional display of the object’s cross sections. This system can produce a high resolution image from an object based on its low frequency (kHz) characteristics.
1995-087 – The base sequence coding for the protein of the human kappa opioid receptor, the deduced amino acid sequence and the cell line transfected with the gene expressing the protein.
1995-072 – A marker for detecting breast cancer and implications for pancreatic cancer. The novel TGFß/estrogen inducible gene (TIEG) has been identified in normal human fetal osteoblasts using differential-display PCR. TIEG is regulated by TGFß and estrogen in breast tissue, osteoblasts and other cell and tissue types. Thus in addition to being an interesting target for gene discovery, TIEG is a useful... Read More
1995-055 – Imaging of Tubular Structures; Systems and methods have been developed for imaging tubular structures in the body using 2D and/or 3D.
1995-051 – Sequence analysis has been used to select synthetic peptides for use in the development of rabbit polyclonal antibodies against each of the known human cytosolic sulfotransferase enzymes. These antibodies, in turn, can be used to characterize these enzymes for both research purposes and in the development of drugs that are metabolized by sulfatino in humans.
1994-101 – Technology Description Hospitals and surgery centers face significant cost pressure when it comes to maintaining materials and supplies. With supply costs representing a significant expense in surgical services, close and careful monitoring is needed to reduce costs and improve efficiencies. Developed at Mayo Clinic, the Supply Inventory Management System (SIMS) is a comprehensive program... Read More
1994-072 – The invention provides an isolated and purified human DNA molecule that encodes human estrogen sulfotransferase (EST, SULT1E1). It also provides cell lines and vectors containing human estrogen sulfotransferase DNA that can be used to express the enzyme. The enzyme is useful for screening drugs that are metabolized by human estrogen sulfotransferase.
1993-058 – Open reading frame gene sequence of the neurotensin receptors from human brain tissue.
1993-030 – Human Thiopurine Methyltransferase (TPMT) Gene Discovery - Stably-transformed cells expressing human thiopurine methyltransferase Human Thiopurine Methyltransferase (TPMT) Gene Discovery. Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine, 6-thioguanine and azathioprine. Patent claims to the DNA coding sequence, amino acid sequence and cell lines and mammals in which... Read More